Supreme Showdown | GenomeWeb

Supreme Showdown

The US Supreme Court is gearing up to hear arguments in the Myriad Genetics gene patenting case on Monday. The Myriad patents cover the isolated BRCA1 and BRCA2 genes, which increase the risk of breast, ovarian, and other cancers, while critics say isolated DNA is a product of nature and, therefore, is not patentable. The implications of a decision in The Association for Molecular Pathology v.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.